About Trevena
Trevena is a company based in Philadelphia (United States) founded in 2007. Trevena has raised $203 million across 11 funding rounds from investors including NIH, HHS and Forest Laboratories. The company has 35 employees as of December 31, 2022. Trevena operates in a competitive market with competitors including Flexion Therapeutics, Tonix Pharma, Cara Therapeutics, Eliem Therapeutics and Ethypharm, among others.
- Headquarter Philadelphia, United States
- Employees 35 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Trevena, Inc.
-
Annual Revenue
$3.13 M (USD)0as on Dec 31, 2023
-
Net Profit
-$40.29 M (USD)24.93as on Dec 31, 2023
-
EBITDA
-$34.4 M (USD)38.04as on Dec 31, 2023
-
Total Equity Funding
$203 M (USD)
in 11 rounds
-
Latest Funding Round
$4 M (USD), Post-IPO
Dec 27, 2023
-
Investors
NIH
& 7 more
-
Employee Count
35
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Trevena
Trevena is a publicly listed company on the OTC with ticker symbol TRVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Trevena
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Key Team
3 people
Operations Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Trevena
Trevena has successfully raised a total of $203M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Trevena
Trevena has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Forest Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for Trevena
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Trevena
Investment portfolio details for Trevena
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Trevena
Detailed financials for Trevena
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trevena Comparisons
Peer comparison for Trevena
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Trevena
Trevena operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Tonix Pharma, Cara Therapeutics, Eliem Therapeutics and Ethypharm, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
Detailed competitors of Trevena
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trevena
Complete news archive for Trevena
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trevena
Trevena was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Trevena is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Trevena is a funded company, having raised a total of $203M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Trevena is 35.
Annual revenue of Trevena is $3.13M as on Dec 31, 2023.
Trevena is a developer of GPCR ligand technology-based therapeutics for cardiovascular diseases and pain. It has three programs in development: TRV027, currently in Phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intravenous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.
Trevena's top competitors include Flexion Therapeutics, Tonix Pharma and Cara Therapeutics.
Yes, Trevena is publicly traded on OTC under the ticker symbol TRVN.
Trevena has 8 investors. Key investors include NIH, HHS, Forest Laboratories, Polaris Partners, and NEA.
The ticker symbol of Trevena is TRVN on OTC.